Comparative Pharmacology
Head-to-head clinical analysis: ALYACEN 1 35 versus TAYTULLA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALYACEN 1 35 versus TAYTULLA.
ALYACEN 1/35 vs TAYTULLA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination hormonal contraceptive: ethinyl estradiol suppresses gonadotropin release via negative feedback on hypothalamic-pituitary axis; norethindrone induces progestational effects including cervical mucus thickening and endometrial changes, inhibiting ovulation and sperm penetration.
Combination of drospirenone, a spironolactone analog with antimineralocorticoid and antiandrogenic activity, and ethinyl estradiol, an estrogen. Suppresses gonadotropins, primarily luteinizing hormone, inhibiting ovulation. Increases cervical mucus viscosity and alters endometrial receptivity.
One tablet (norethindrone 1 mg and ethinyl estradiol 35 mcg) orally once daily for 21 consecutive days, followed by 7 days of placebo or no tablets.
One capsule orally once daily for 24 weeks.
None Documented
None Documented
Norethindrone: 8-11 hours (terminal); ethinyl estradiol: 10-20 hours (terminal). The half-life supports once-daily dosing for oral contraceptive efficacy.
Terminal elimination half-life: 30 hours. Provides once-daily dosing with steady-state achieved after 7 days.
Renal excretion of metabolites (primarily ethinyl estradiol and norethindrone conjugates) accounts for approximately 50-60% of elimination; fecal excretion accounts for 30-40%. Unchanged drug excretion is minimal (<5%).
Renal: ~60% as unchanged drug; Fecal: ~40% as metabolites and unchanged drug.
Category C
Category C
Oral Contraceptive
Oral Contraceptive